AI specialists Enveda and Basecamp rake in the cash
AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Roche, Viking, and Syntis showcase obesity drug candidates
A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.
Roche's IgAN hopeful sefaxersen passes phase 3 test
Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
Amgen's Horizon buyout delivers Sjögren's disease win
Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
Pharma leaders urge Europe to halt 'slow agony' of decline
Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit